LITTLE FALLS, N.J.,
April 18, 2018 /PRNewswire/
-- Cantel Medical Corp. (NYSE: CMD) announced today
that it has received U.S. Food and Drug Administration (FDA)
510 (k) clearance for its ADVANTAGE PLUS® Pass-Thru automated
endoscope reprocessor (AER).
The ADVANTAGE PLUS® Pass-Thru AER has been clinically proven to
high-level disinfect the most commonly used endoscopes, including
duodenoscopes. The machine also uses a unique pass-through design
that supports one-way workflow to ensure the highest quality in
infection prevention by reducing the risk of human error,
distraction and unintended lapses in cleaning protocols. In
addition, the hard-wall separation between dirty and clean
reprocessing areas is designed to prevent recontamination of
reprocessed endoscopes, ensuring safe, patient-ready endoscopes for
every procedure. ADVANTAGE PLUS® Pass-Thru AER is the first
pass-through AER available in the United
States.
The transformational pass-through capability and integrated
smart technology of ADVANTAGE PLUS® Pass-Thru AER provides fast and
efficient turnover. The high-performance disinfection system and
hands-free operation reduces scope handling, and allows the
reprocessing of 4-5 scopes in just over one hour. The ADVANTAGE
PLUS® Pass-Thru AER has been validated for use with Cantel's
proprietary RAPICIDE® PA Disinfectant.
"The FDA clearance of ADVANTAGE PLUS® Pass-Thru AER further
expands our rapidly growing endoscopy portfolio and delivers on our
commitment to safeguard the world from infections through
innovative, market leading technologies," stated Dave Hemink, President of Cantel's
Endoscopy Division. "As a leader in infection prevention for over
20 years, Cantel is thrilled to announce the availability of this
best practice technology in automated endoscope reprocessing to our
U.S. customers."
"We strive to deliver real life infection prevention solutions
to address the complexities our customers face in setting up
successful endoscopy departments," said Bill Haydon, Vice President Global Marketing and
Business Development, Endoscopy. "We believe the ADVANTAGE PLUS®
Pass-Thru AER's availability will transform our customers'
experiences by improving department efficiencies and workflow while
maintaining the integrity of the cleaning process and supporting
patient safety."
The ADVANTAGE PLUS® Pass-Thru AER is built upon the proven
technology of the industry-leading ADVANTAGE PLUS® AER to
consistently deliver high-level disinfection to support infection
prevention efforts of endoscopy units worldwide. This launch
further supports Cantel's Complete Circle of Protection, an
infection prevention program designed to help streamline
reprocessing workflow, improve department efficiency and reduce the
risk of infection.
The ADVANTAGE PLUS® Pass-Thru AER is now available for customer
installation. For more information, please visit
https://bit.ly/2ufSyt2.
About Cantel Medical Corp.
Cantel Medical is a leading global company dedicated to
delivering innovative infection prevention and control products and
services for patients, caregivers, and other healthcare providers
which improve outcomes, enhance safety and help save
lives. Our products include specialized medical device
reprocessing systems for endoscopy and renal dialysis, advanced
water purification equipment, sterilants, disinfectants and
cleaners, sterility assurance monitoring products for hospitals and
dental clinics, disposable infection control products primarily for
dental and GI endoscopy markets, dialysate concentrates, hollow
fiber membrane filtration and separation products. Additionally, we
provide technical service for our products.
For further information, visit the Cantel website at
www.cantelmedical.com.
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements involve a number of risks and uncertainties,
including, without limitation, the risks detailed in Cantel's
filings and reports with the Securities and Exchange Commission.
Such forward-looking statements are only predictions, and actual
events or results may differ materially from those projected or
anticipated.
View original content with
multimedia:http://www.prnewswire.com/news-releases/cantel-medical-receives-fda-510k-clearance-to-market-advantage-plus-pass-thru-automated-endoscope-reprocessor-300631885.html
SOURCE Cantel Medical Corp.